<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" dtd-version="1.0" specific-use="sps-1.5" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">yzqNHCsknnhVT4wjjsKMKsv</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2017000400370</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20170047</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Viewpoint</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Challenges for the Implementation of the First Large-Scale Rheumatic Heart Disease Screening Program in Brazil: The PROVAR Study Experience</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Julia Pereira Afonso dos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carmo</surname>
            <given-names>Gabriel Assis Lopes do</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beaton</surname>
            <given-names>Andrea Zawacki</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Louren&#231;o</surname>
            <given-names>Tain&#225; Vitti</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Diamantino</surname>
            <given-names>Adriana Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nunes</surname>
            <given-names>Maria do Carmo Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sable</surname>
            <given-names>Craig</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nascimento</surname>
            <given-names>Bruno Ramos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <institution content-type="orgdiv1">Hospital das Cl&#237;nicas</institution>
        <addr-line>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital das Cl&#237;nicas da Universidade Federal de Minas Gerais, MG - Brazil</institution>
        <institution content-type="normalized">Universidade Federal de Minas Gerais</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgname">Childrens National Health System</institution>
        <addr-line>
          <named-content content-type="state">Washington</named-content>
        </addr-line>
        <country country="US">EUA</country>
        <institution content-type="original">Childrens National Health System, Washington - EUA</institution>
      </aff>
      <author-notes>
        <corresp id="c1"><bold>Mailing Address: Bruno Ramos Nascimento</bold>, Rua Tenente Garro, 137, apto: 601. Postal Code 30240-360, Santa Efig&#234;nia, Belo Horizonte, MG - Brazil. E-mail: <email>ramosnas@cardiol.br</email>; <email>ramosnas@gmail.com</email>
				</corresp>
        <fn fn-type="con">
          <p>
            <bold>Author contributions</bold>
          </p>
          <p>Conception and design of the research: Santos JPA, Carmo GAL, Beaton AZ, Sable C, Nascimento BR; Acquisition of data: Santos JPA, Carmo GAL, Louren&#231;o TV, Diamantino AC, Nunes MCP, Nascimento BR; Analysis and interpretation of the data: Beaton AZ, Nunes MCP, Sable C, Nascimento BR; Statistical analysis: Carmo GAL, Beaton AZ, Nunes MCP, Nascimento BR; obtaining funding: Beaton AZ, Sable C, Nascimento BR; Writing of the manuscript: Santos JPA, Louren&#231;o TV; Critical revision of the manuscript for intellectual content: Carmo GAL, Beaton AZ, Sable C, Nascimento BR.</p>
        </fn>
        <fn fn-type="conflict">
          <p>
            <bold>Potential Conflict of Interest</bold>
          </p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>04</month>
        <year>2017</year>
      </pub-date>
      <volume>108</volume>
      <issue>4</issue>
      <fpage>370</fpage>
      <lpage>374</lpage>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>11</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>10</day>
          <month>11</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>12</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Rheumatic Heart Disease</kwd>
        <kwd>Mass Screening</kwd>
        <kwd>Echocardiography</kwd>
        <kwd>Child</kwd>
        <kwd>Adolescent</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Rheumatic Heart Disease (RHD) is the cardiac consequence of acute rheumatic fever (ARF), an inflammatory disease triggered by streptococcal pharyngitis. Although the prevalence of RHD has decreased in high-income countries, lack of social and economic development and poor primary prevention - mainly in in low- and middle-income countries - perpetuate an environment where RHD remains endemic. It is estimated that RHD continues to affect nearly 33 million people worldwide.<xref ref-type="bibr" rid="B1">1</xref> According to the World Health Organization (WHO), RHD is responsible for 1-1.5% of all cardiovascular deaths and 3-4% of cardiovascular Disability-Adjusted Life Years (DALYs).<xref ref-type="bibr" rid="B2">2</xref> In Brazil, according to the Unified Health System (SUS), there were 26,054 hospital admissions for ARF (45% with cardiac compromise) between 2008 and 2015, and the total cost to SUS was US$3.5 million, a number that is most likely underestimated.<xref ref-type="bibr" rid="B3">3</xref>
			</p>
      <p>The main burden of RHD to public health systems consists of repeated hospital admissions and cardiac surgeries in the following decades after initial cardiac damage. If RHD is detected in its early stages, secondary prophylaxis (regular penicillin injections) can be initiated to prevent new episodes of ARF, avoiding further valve damage and progression of RHD. In high prevalence regions, RHD meets the traditional screening criteria defined by Wilson and Jungner,<xref ref-type="bibr" rid="B4">4</xref> although the long-term clinical significance of latent RHD is not entirely clear. Previous studies have demonstrated, however, that in 38 to 68% of asymptomatic RHD patients, echocardiographic findings show that abnormalities persist, and progress in 4 to 16%,<xref ref-type="bibr" rid="B5">5</xref> reinforcing the importance of early diagnosis in susceptible populations.</p>
      <p>The PROVAR study (<italic>Programa de Rastreamento da Valvopatia Reum&#225;tica -</italic> Rheumatic Heart Disease Screening Program) is the first large-scale echocardiographic screening program in Brazil, using echocardiography to estimate the prevalence of latent RHD in asymptomatic children between 5 and 18 years old attending public schools of underserved areas of the cities Belo Horizonte, Montes Claros and Bocai&#250;va, in the Brazilian State of Minas Gerais. Minas Gerais is the second most populous Brazilian state (&gt;20 million inhabitants) and has a large territory, great geographical diversity and is marked by economic discrepancies between its different regions. This project is a clinical and research collaboration between the University Hospital of <italic>Universidade Federal de Minas Gerais</italic> (UFMG), Brazil, and the Children's National Health System (CNHS) in Washington DC, United States of America (USA).</p>
      <sec>
        <title>Implementation of the study</title>
        <p>The regulatory process started in the end of 2013, and the study was approved by the institutional review boards of UFMG and CNHS, as well as the State Boards of Health and Education. Legal sectors then analyzed the proposal and approved it, and there was no extra cost for the government or patients. The Department of Education selected schools with the highest socioeconomic vulnerability, with a special interest in areas with limited access to healthcare. Prior to screening, an educational curriculum was implemented, including lectures and printed material, for students and their parents, teachers and school staff regarding the importance of streptococcal pharyngitis, ARF and RHD. Parents were asked to sign an informed consent form - a requirement of Brazilian research regulations. Non-physician personnel started echocardiographic screening in July 2014 after a 12-week hands-on training supervised by an expert cardiologist and online RHD education modules (WiRED International, <ext-link ext-link-type="uri" xlink:href="http://www.wiredhealthresources.net/EchoProject/index.html">http://www.wiredhealthresources.net/EchoProject/index.html</ext-link>). They used portable (GE Vivid Q<sup>&#174;</sup>) and handheld (GE VSCAN&#174;) machines. Images were uploaded into dedicated cloud computing systems or Dropbox&#174; and remotely interpreted by experienced cardiologists at UFMG (board certified by the Brazilian Society of Echocardiography) and CNHS using telemedicine resources (<xref ref-type="fig" rid="f1">Figure 1</xref>).<xref ref-type="bibr" rid="B6">6</xref> We used the World Heart Federation criteria for the diagnosis of RHD.<xref ref-type="bibr" rid="B7">7</xref> Two experts blindly interpreted 10% of all acquired studies including 100% of the studies initially flagged as abnormal. In case of discrepancies during this process, a third expert blindly reviewed the images and a consensus diagnosis was reached.</p>
        <p>
          <fig id="f1">
            <label>Figure 1</label>
            <caption>
              <title>Operational flowchart of the PROVAR study: a) selection of schools in low-income areas; b) educational process; c) acquisition of echocardiographic images by non-physicians, using portable and handheld echo machines; d) image upload to cloud computing solutions with image viewing and measurement capability (LifeImage&#174; (Newton, MA, USA) and ViTel Net&#174;, (McLean, VA, USA)) for DICOM images from standard portable machines and secure Dropbox&#174; plus dedicated Gateway&#174; software for VSCAN; e) download and interpretation via telemedicine by cardiologists in Brazil and the United States (Sable, C. and Nascimento, B.R.).</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-108-04-0370-70047-gf01.jpg"/></fig>
        </p>
        <p>When abnormalities were detected during the screening echocardiogram, a medical student called the child's parents to schedule a follow-up standard exam, which was performed by an experienced pediatric cardiologist at the university's hospital. Borderline RHD cases had a clinical consult and a follow up echocardiogram scheduled within one year. For patients found to have definite RHD based on the screening and follow-up echocardiogram, in addition to the referral to a specialized outpatient clinic, penicillin prophylaxis was initiated and more frequent follow-up echocardiograms were recommended based on the observations of subsequent visits.</p>
      </sec>
      <sec>
        <title>Initial results</title>
        <p>The PROVAR team has educated over 20,000 children on RHD, and has performed over 9,000 echocardiograms in 32 schools.<xref ref-type="bibr" rid="B8">8</xref> In the published analysis of 5,996 asymptomatic children from 21 schools, the overall prevalence of RHD was 4.2%, including 3.7% borderline (N = 221) and 0.5% definitive (N = 30). The inclusion of borderline patients as positive screening may raise some doubts, considering the available data. However, we believe this should be done, since this group seems to have increased the risk of progression to clinical RHD (<xref ref-type="fig" rid="f2">Figure 2</xref>).<xref ref-type="bibr" rid="B5">5</xref><sup>,</sup><xref ref-type="bibr" rid="B9">9</xref> Children with cardiovascular symptoms (self-reported or reported by teachers/parents) that eventually presented to the program were directly referred to tertiary care. It is important to note that non-physician personnel performed the screening echocardiograms. Only physicians are allowed to perform and read echocardiograms in Brazil, and we were able to conduct the study because it was a research protocol.</p>
        <p>
          <fig id="f2">
            <label>Figure 2</label>
            <caption>
              <title>Progressive presentation of Rheumatic Heart Disease over time (adapted by Carmo, G.A.L. from Z&#252;hlke LJ and Steer AC.<xref ref-type="bibr" rid="B5">5</xref>).</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-108-04-0370-70047-gf02.jpg"/></fig>
        </p>
        <p>The accuracy of these non-physicians (nurses, technicians and medical students) for basic interpretation of simplified screening exams was tested and had good results: overall sensitivity of 83% and specificity of 85%.<xref ref-type="bibr" rid="B10">10</xref> Moreover, the educational process has proven to be effective, with a median 20% increase in knowledge about RHD, evaluated through structured pre- and post-tests applied to more than 1,100 school children.<xref ref-type="bibr" rid="B11">11</xref>
				</p>
      </sec>
      <sec>
        <title>Main challenges</title>
        <p>There were several challenges during the implementation and conduction of the PROVAR study. During the initial ethics approval - which took almost 90 days in Brazil - some resistance from the Board of Education and Health was observed, mainly related to research procedures and the impact on the school routine. Some modifications to the consent forms were required, which took an extra 4 months. There was also questioning by the Board of Health, related to concerns about task-shifting (which could be questioned by medical and nursing councils) and the impact of screening on the population: referral strategies, availability of penicillin for all positive cases - considering the shortage observed in Brazil - and information for families with children with positive exams to avoid stigmatization. </p>
        <p>During the initial steps of the field study, the PROVAR team faced several challenges. At first, the main challenges were related to the lack of involvement of school representatives with the program and lack of understanding possible benefits. Overall, there was low parental engagement with the project with the poorest attendance to educational sessions seen in the lowest socioeconomic status areas. The proportion of signed informed consents was low (about 35%: 5,996 out of 17,000 children)<xref ref-type="bibr" rid="B8">8</xref> especially among older students, even after the educational process. Also, some school principals refused to participate despite approval by the ethics committee and government authorities. Finally, organizing the kids for screening, especially the youngest age groups, was a challenge: removing the children from the classroom, getting them to undress/dress and organized in a line, collecting demographic data, etc. Follow-up meetings with the Boards of Education and local delegates were scheduled on a regular basis to assess weaknesses and special needs of different communities, and to encourage school staff to support the project locally. Screening in primary care centers with population education through the Family Health Program - a plan for the following years - may also be an effective strategy to increase the scope of the program.</p>
        <p>There were also several challenges for follow-up visits. Phone contact with parents was often not possible because the children did not have the contact information, numbers changed frequently, and schools are not always authorized to disclose contact information. In addition, 35% of families failed to show up for scheduled appointments. This may presumably be, in part, due to patients being asymptomatic and families not being convinced of the importance of monitoring. Based on conversations with parents who have not returned for the follow-up, our team hypothesizes that financial constraints, living in distant neighborhoods and impossibility to miss a workday also contributed to the lack of compliance with recommendations for follow up in the study protocol. However, data about the reasons for the low compliance were not systematically collected. Some strategies, such as subsequent educational calls and flexible follow-up dates have been recently tested, with relative success. There is also a plan to provide follow-up echocardiograms in the schools, immediately after the screening process, to improve follow-up and referral rates. Additionally, educational and public awareness materials for different scenarios are under development, considering the questions posed by the families.</p>
      </sec>
      <sec>
        <title>Future directions</title>
        <p>Fighting RHD is a challenge for Brazil. Understanding the burden of the disease and how it affects the health system is the primary objective of PROVAR. The PROVAR program will continue to screen for RHD in underserved areas, but we are now expanding our efforts to private schools, where students' socioeconomic conditions are much better. A much lower prevalence is anticipated in this "control" population.</p>
        <p>Authorities should be prepared to effectively eradicate RHD. To do so, we believe ARF and RHD should be included in the list of notifiable diseases, since these conditions have a considerably high incidence in Brazil. Group A streptococcal infections (triggers for ARF) are communicable from patient to patient and transmission can be eliminated with eradication.<xref ref-type="bibr" rid="B12">12</xref> Also, by identifying early RHD, secondary prophylaxis can be initiated to prevent disease progression and late consequences such as heart failure, endocarditis, arrhythmias, stroke and heart valve surgeries.</p>
        <p>The next steps of PROVAR are related to the diagonal integration of RHD screening in primary care. This strategy is now being implemented in Montes Claros (MG, Brazil) (2 primary care centers have already been enrolled) and will be launched in Belo Horizonte and Nova Lima (MG - Brazil) in the following months, also including screening for other degenerative and congenital valve conditions. For this purpose, primary care physicians will also be trained in basic echocardiographic skills for routine evaluation of different age groups, utilizing the same telemedicine infrastructure for uploads and remote interpretation. We believe this integration is a crucial step for long-term sustainability of echocardiographic screening and for its integration into healthcare policies, and will allow assessment of the ideal screening strategies, including cost-effectiveness analysis. If RHD screening in these scenarios proves to be feasible and cost-effective, the final step would be to include it as a priority for the discussion of the Public Health System budget in the long run.</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>
          <bold>Sources of Funding</bold>
        </p>
        <p>This study was funded by Verizon Foundation (U.S.A.), Funda&#231;&#227;o de Amparo &#224; Pesquisa de Minas Gerais (FAPEMIG) and Conselho Nacional de Desenvolvimento CIent&#237;fico e Tecnol&#243;gico (CNPq).</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Study Association</bold>
        </p>
        <p>This study is not associated with any thesis or dissertation work.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>The PROVAR investigators would like to thank Verizon for supporting and funding the program, General Electric Healthcare for providing echocardiography equipment for this program, and ViTel Net&#174; for their collaboration and contribution to creating an RHD cloud platform and Edwards Foundation for supporting the following steps of the primary care valve program. The Telehealth Network of Minas Gerais was funded by the State Government of Minas Gerais, by its Health Department (<italic>Secretaria de Estado da Sa&#250;de de Minas Gerais</italic>) and its research agency FAPEMIG (<italic>Funda&#231;&#227;o de Amparo &#224; Pesquisa de Minas Gerais</italic>), and by the Brazilian Government, including the Ministries of Health and Science and Technology and their research and innovation agencies, CNPq (<italic>Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico</italic>) and FINEP (<italic>Financiadora de Estudos e Projetos</italic>).</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1 Global Burden of Disease Study 2013 Collaboration. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Global Burden of Disease Study 2013 Collaboration</collab>
          </person-group>
          <article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013</article-title>
          <source>Lancet</source>
          <year>2015</year>
          <volume>386</volume>
          <issue>9995</issue>
          <fpage>743</fpage>
          <lpage>800</lpage>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2 Mendis S, Puska P, Norrvin B. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011.</mixed-citation>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Mendis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Puska</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Norrvin</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <source>Global atlas on cardiovascular disease prevention and control</source>
          <year>2011</year>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3 Minist&#233;rio da Sa&#250;de. Indicadores e dados b&#225;sicos - Brasil, 2015. DATASUS - Departamento de Inform&#225;tica do SUS. [Acesso em 2016 Out 10]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://www.datasus.gov.br/idb">http://www.datasus.gov.br/idb</ext-link>
				</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Minist&#233;rio da Sa&#250;de</collab>
          </person-group>
          <source>Indicadores e dados b&#225;sicos - Brasil, 2015. DATASUS - Departamento de Inform&#225;tica do SUS</source>
          <date-in-citation content-type="access-date">2016 Out 10</date-in-citation>
          <comment>Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://www.datasus.gov.br/idb">http://www.datasus.gov.br/idb</ext-link>
					</comment>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4 Andermann A, Blancquaert I, Beauchamp S, D&#233;ry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317-9.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andermann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Blancquaert</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Beauchamp</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>D&#233;ry</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years</article-title>
          <source>Bull World Health Organ</source>
          <year>2008</year>
          <volume>86</volume>
          <issue>4</issue>
          <fpage>317</fpage>
          <lpage>319</lpage>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5 Z&#252;hlke LJ, Steer AC. Estimates of the global burden of rheumatic heart disease. Global Heart. 2013;8(3):189-95.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Z&#252;hlke</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Steer</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Estimates of the global burden of rheumatic heart disease</article-title>
          <source>Global Heart</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>3</issue>
          <fpage>189</fpage>
          <lpage>195</lpage>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6 Lopes EL, Beaton AZ, Nascimento BR, Tompsett A, Dos Santos JP, Perlman L, et al; Programa de RastreamentO da Valvopatia Reum&#225;tica (PROVAR) investigators. Telehealth solutions to enable global collaboration in rheumatic heart disease screening. J Telemed Telecare. 2016 Nov 4. pii: 1357633X16677902. [Epub ahead of print]</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopes</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Beaton</surname>
              <given-names>AZ</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Tompsett</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dos Santos</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Perlman</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
            <collab>Programa de RastreamentO da Valvopatia Reum&#225;tica</collab>
          </person-group>
          <article-title>Telehealth solutions to enable global collaboration in rheumatic heart disease screening</article-title>
          <source>J Telemed Telecare</source>
          <day>04</day>
          <month>11</month>
          <year>2016</year>
          <pub-id pub-id-type="pii">1357633X16677902</pub-id>
          <comment>Epub ahead of print</comment>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7 Rem&#233;nyi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline. Nat Rev Cardiol. 2012;9(5):297-309.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rem&#233;nyi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Steer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kado</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline</article-title>
          <source>Nat Rev Cardiol</source>
          <year>2012</year>
          <volume>9</volume>
          <issue>5</issue>
          <fpage>297</fpage>
          <lpage>309</lpage>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8 Nascimento BR, Beaton AZ, Nunes MC, Diamantino AC, Carmo GA, Oliveira KK, et al; PROVAR (Programa de RastreamentO da VAlvopatia Reum&#225;tica) investigators. Echocardiographic prevalence of rheumatic heart disease in Brazilian schoolchildren: Data from the PROVAR study. Int J Cardiol. 2016;219:439-45.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Beaton</surname>
              <given-names>AZ</given-names>
            </name>
            <name>
              <surname>Nunes</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Diamantino</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Carmo</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>KK</given-names>
            </name>
            <etal/>
            <collab>Programa de RastreamentO da VAlvopatia Reum&#225;tica</collab>
          </person-group>
          <article-title>Echocardiographic prevalence of rheumatic heart disease in Brazilian schoolchildren: Data from the PROVAR study</article-title>
          <source>Int J Cardiol</source>
          <year>2016</year>
          <volume>219</volume>
          <fpage>439</fpage>
          <lpage>445</lpage>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9 R&#233;mond M, Atkinson D, White A, Brown A, Carapetis J, Remenyi B, et al. Are minor echocardiographic changes associated with an increased risk of acute rheumatic fever or progression to rheumatic heart disease? Int J Cardiol. 2015;198:117-22.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>R&#233;mond</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Atkinson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carapetis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Remenyi</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Are minor echocardiographic changes associated with an increased risk of acute rheumatic fever or progression to rheumatic heart disease?</article-title>
          <source>Int J Cardiol</source>
          <year>2015</year>
          <volume>198</volume>
          <fpage>117</fpage>
          <lpage>122</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10 Beaton A, Nascimento BR, Diamantino AC, Pereira GT, Lopes EL, Miri CO, et al. Efficacy of a standardized computer-based training curriculum to teach echocardiographic identification of rheumatic heart disease to nonexpert users. Am J Cardiol. 2016;117(11):1783-9.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beaton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Diamantino</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Miri</surname>
              <given-names>CO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of a standardized computer-based training curriculum to teach echocardiographic identification of rheumatic heart disease to nonexpert users</article-title>
          <source>Am J Cardiol</source>
          <year>2016</year>
          <volume>117</volume>
          <issue>11</issue>
          <fpage>1783</fpage>
          <lpage>1789</lpage>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation>11 Nascimento BR, Beaton AZ, Chequer G, Oliveira KK, Oliveira CM, Lopes EL, Knowledge - Data From the PROVAR Study. Circulation. 2015;132(Suppl 3):A18513.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Beaton</surname>
              <given-names>AZ</given-names>
            </name>
            <name>
              <surname>Chequer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>Knowledge - Data From the PROVAR Study</article-title>
          <source>Circulation</source>
          <year>2015</year>
          <volume>132</volume>
          <supplement>Suppl 3</supplement>
          <fpage>A18513</fpage>
          <lpage>A18513</lpage>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation>12 Teixeira MdG, Penna GO, Risi JB, Penna ML, Alvim MF, Moraes JC, et al. Sele&#231;&#227;o das doen&#231;as de notifica&#231;&#227;o compuls&#243;ria: crit&#233;rios e recomenda&#231;&#245;es para as tr&#234;s esferas de governo. Inf Epideliol SUS. 1998;7(1):22.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teixeira</surname>
              <given-names>MdG</given-names>
            </name>
            <name>
              <surname>Penna</surname>
              <given-names>GO</given-names>
            </name>
            <name>
              <surname>Risi</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Penna</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Alvim</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Moraes</surname>
              <given-names>JC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sele&#231;&#227;o das doen&#231;as de notifica&#231;&#227;o compuls&#243;ria: crit&#233;rios e recomenda&#231;&#245;es para as tr&#234;s esferas de governo</article-title>
          <source>Inf Epideliol SUS</source>
          <year>1998</year>
          <volume>7</volume>
          <issue>1</issue>
          <fpage>22</fpage>
          <lpage>22</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="s1" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Ponto de Vista</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Desafios para a Implanta&#231;&#227;o do Primeiro Programa de Rastreamento da Cardiopatia Reum&#225;tica em Larga Escala no Brasil: A Experi&#234;ncia do Estudo PROVAR</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Julia Pereira Afonso dos</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carmo</surname>
            <given-names>Gabriel Assis Lopes do</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beaton</surname>
            <given-names>Andrea Zawacki</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Louren&#231;o</surname>
            <given-names>Tain&#225; Vitti</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Diamantino</surname>
            <given-names>Adriana Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nunes</surname>
            <given-names>Maria do Carmo Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sable</surname>
            <given-names>Craig</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nascimento</surname>
            <given-names>Bruno Ramos</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">1</xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
      </contrib-group>
      <aff id="aff3">
        <label>1</label>
        <institution content-type="original">Hospital das Cl&#237;nicas da Universidade Federal de Minas Gerais, MG - Brasil</institution>
      </aff>
      <aff id="aff4">
        <label>2</label>
        <institution content-type="original">Childrens National Health System, Washington - EUA</institution>
      </aff>
      <author-notes>
        <corresp id="c2"><bold>Correspond&#234;ncia: Bruno Ramos Nascimento</bold>, Rua Tenente Garro, 137, apto 601. CEP 30240-360, Santa Efig&#234;nia, Belo Horizonte, MG - Brasil. E-mail: <email>ramosnas@cardiol.br</email>; <email>ramosnas@gmail.com</email>
				</corresp>
        <fn fn-type="con">
          <p>
            <bold>Contribui&#231;&#227;o dos autores</bold>
          </p>
          <p>Concep&#231;&#227;o e desenho da pesquisa: Santos JPA, Carmo GAL, Beaton AZ, Sable C, Nascimento BR; Obten&#231;&#227;o de dados: Santos JPA, Carmo GAL, Louren&#231;o TV, Diamantino AC, Nunes MCP, Nascimento BR; An&#225;lise e interpreta&#231;&#227;o dos dados: Beaton AZ, Nunes MCP, Sable C, Nascimento BR; An&#225;lise estat&#237;stica: Carmo GAL, Beaton AZ, Nunes MCP, Nascimento BR; Obten&#231;&#227;o de financiamento: Beaton AZ, Sable C, Nascimento BR; Reda&#231;&#227;o do manuscrito: Santos JPA, Louren&#231;o TV; Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante: Carmo GAL, Beaton AZ, Sable C, Nascimento BR.</p>
        </fn>
        <fn fn-type="conflict">
          <p>
            <bold>Potencial conflito de interesses</bold>
          </p>
          <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
        </fn>
      </author-notes>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Cardiopatia Reum&#225;tica</kwd>
        <kwd>Programas de Rastreamento</kwd>
        <kwd>Ecocardiografia</kwd>
        <kwd>Crian&#231;as</kwd>
        <kwd>Adolescente</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introdu&#231;&#227;o</title>
        <p>Cardiopatia reum&#225;tica (CR) &#233; a consequ&#234;ncia card&#237;aca da febre reum&#225;tica aguda (FRA), doen&#231;a inflamat&#243;ria causada pela faringite estreptoc&#243;cica. Embora a preval&#234;ncia de CR esteja diminuindo em pa&#237;ses de alto poder aquisitivo, o subdesenvolvimento econ&#244;mico e social e preven&#231;&#227;o prim&#225;ria deficiente principalmente em pa&#237;ses de poder aquisitivo baixo e m&#233;dio - perpetuam um cen&#225;rio em que a CR permanece end&#234;mica. Estima-se que a CR ainda afete aproximadamente 33 milh&#245;es de pessoas no mundo.<xref ref-type="bibr" rid="B1">1</xref> De acordo com a Organiza&#231;&#227;o Mundial de Sa&#250;de (OMS), a CR &#233; respons&#225;vel por 1-1,5% de todas as mortes cardiovasculares e 3-4% de Expectativa de Vida Corrigida por Incapacidade (EVCI/DALYs) cardiovascular.<xref ref-type="bibr" rid="B2">2</xref> No Brasil, de acordo com o SUS (Sistema &#218;nico de Sa&#250;de), entre 2008 e 2015, houve um total de 26.054 hospitaliza&#231;&#245;es por FRA (45% com comprometimento card&#237;aco), e o custo total para o SUS foi de US$ 3,5 milh&#245;es, sendo este valor esse provavelmente subestimado.<xref ref-type="bibr" rid="B3">3</xref>
				</p>
        <p>O maior impacto representado pela CR para sistemas p&#250;blicos de sa&#250;de consiste de repetidas hospitaliza&#231;&#245;es e cirurgias card&#237;acas necess&#225;rias d&#233;cadas ap&#243;s o comprometimento card&#237;aco inicial. Quando a CR &#233; detectada precocemente, a profilaxia secund&#225;ria (inje&#231;&#245;es regulares de penicilina) pode ser iniciada para prevenir novos epis&#243;dios de FRA, evitando, assim, danos valvares e progress&#227;o da CR. Em regi&#245;es de alta preval&#234;ncia, a CR preenche os crit&#233;rios de rastreamento definidos por Wilson e Jungner,<xref ref-type="bibr" rid="B4">4</xref> embora a signific&#226;ncia cl&#237;nica de longo prazo da CR latente ainda n&#227;o esteja clara. Todavia, estudos pr&#233;vios demonstraram que em 38 a 68% dos pacientes assintom&#225;ticos com CR, achados ecocardiogr&#225;ficos mostram que anormalidades persistem, e progridem em 4 a 16%,<xref ref-type="bibr" rid="B5">5</xref> refor&#231;ando a import&#226;ncia do diagn&#243;stico precoce em popula&#231;&#245;es suscet&#237;veis.</p>
        <p>O estudo PROVAR (Programa de Rastreamento da Valvopatia Reum&#225;tica) &#233; o primeiro programa de rastreamento ecocardiogr&#225;fico em grande escala do Brasil, utilizando a ecocardiografia para estimar a preval&#234;ncia de CR latente em crian&#231;as assintom&#225;ticas entre 5 e 18 anos de idade, alunos de escolas p&#250;blicas em &#225;reas carentes de Belo Horizonte, Montes Claros e Bocai&#250;va no Estado de Minas Gerais. Minas Gerais &#233; o segundo Estado Brasileiro mais populoso (&gt; 20 milh&#245;es de habitantes), tem amplo territ&#243;rio, grande diversidade geogr&#225;fica e alta discrep&#226;ncia econ&#244;mica entre suas diferentes regi&#245;es. Esse projeto &#233; uma colabora&#231;&#227;o cl&#237;nica e de pesquisa entre o Hospital das Cl&#237;nicas da Universidade Federal de Minas Gerais (UFMG) e o <italic>Children's National Health System</italic> (CNHS) em Washington, DC, nos Estados Unidos.</p>
        <sec>
          <title>Implementa&#231;&#227;o do estudo</title>
          <p>O processo regulat&#243;rio come&#231;ou no final de 2013, e o estudo foi aprovado pelos comit&#234;s de &#233;tica em pesquisa da UFMG e CNHS, bem como pelas Secretarias Estaduais de Sa&#250;de e Educa&#231;&#227;o. A proposta foi ent&#227;o analisada e aprovada por setores jur&#237;dicos, e n&#227;o houve custos extras para o governo ou pacientes. A Secretaria Estadual de Educa&#231;&#227;o selecionou escolas com a maior vulnerabilidade socioecon&#244;mica, com interesse especial em &#225;reas de acesso limitado ao sistema de sa&#250;de. Antes do rastreamento, implementou-se um processo educacional, incluindo palestras e materiais impressos, para alunos e seus pais, professores e funcion&#225;rios das escolas sobre a import&#226;ncia de faringite estreptoc&#243;cica, FRA e CR. Pediu-se que os pais assinassem um termo de consentimento livre e esclarecido, requerido por regulamenta&#231;&#245;es de pesquisas no Brasil. Membros n&#227;o-m&#233;dicos da equipe come&#231;aram o rastreamento ecocardiogr&#225;fico em julho de 2014, ap&#243;s treinamento pr&#225;tico de 12 semanas supervisionado por um especialista em cardiologia e m&#243;dulos educacionais online sobre CR (WiRED International, <ext-link ext-link-type="uri" xlink:href="http://www.wiredhealthresources.net/EchoProject/index.html">http://www.wiredhealthresources.net/EchoProject/index.html</ext-link>). Foram utilizados equipamentos port&#225;teis (GE Vivid Q&#174;) e ultraport&#225;teis (GE VSCAN&#174;). As imagens foram carregadas em sistemas dedicados de computa&#231;&#227;o em nuvem ou no Dropbox&#174; e interpretadas remotamente por cardiologistas especialistas da UFMG (certificados pela Sociedade Brasileira de Ecocardiografia) e da CNHS por meio de recursos de telemedicina (<xref ref-type="fig" rid="f3">Figura 1</xref>).<xref ref-type="bibr" rid="B6">6</xref> Utilizou-se os crit&#233;rios da Federa&#231;&#227;o Mundial do Cora&#231;&#227;o (<italic>World Heart Federation -</italic> WHF) para o diagn&#243;stico de CR.<xref ref-type="bibr" rid="B7">7</xref> Dois especialistas interpretaram cegamente 10% de todos os estudos adquiridos, incluindo 100% dos estudos marcados como anormais. Em caso de discrep&#226;ncias durante o processo, um terceiro especialista realizava uma revis&#227;o cega das imagens para que um consenso fosse obtido. Quando anormalidades foram encontradas durante o ecocardiograma de rastreamento, um estudante de medicina ligava para os pais da crian&#231;a para agendar um ecocardiograma padr&#227;o de seguimento feito por um cardiologista pedi&#225;trico experiente no hospital da universidade. Casos em que havia possibilidade da presen&#231;a de CR passaram por consulta cl&#237;nica e ecocardiograma de seguimento agendados no prazo de um ano. Para pacientes diagnosticados com CR definitiva, com base nos ecocardiogramas de rastreamento e follow-up, al&#233;m do encaminhamento a um ambulat&#243;rio especializado, iniciou-se a profilaxia com penicilina e foram recomendados ecocardiogramas de follow-up mais frequentes com base nas observa&#231;&#245;es das visitas subsequentes.</p>
          <p>
            <fig id="f3">
              <label>Figura 1</label>
              <caption>
                <title>Fluxograma operacional do estudo PROVAR: A) sele&#231;&#227;o de escolas em &#225;reas de baixa renda; B) processo educativo; C) aquisi&#231;&#227;o de imagens ecocardiogr&#225;ficas por n&#227;o-m&#233;dicos, utilizando equipamentos port&#225;teis de ecocardiografia; D) carregamento de imagens para sistemas de computa&#231;&#227;o em nuvem com capacidade de visualiza&#231;&#227;o e mensura&#231;&#227;o de imagens [LifeImage&#174; (Newton, MA, EUA) e ViTel Net&#174;, (McLean, VA, EUA)] para imagens DICOM de equipamentos port&#225;teis padr&#227;o e Dropbox&#174; seguro e software Gateway&#174; dedicado para VSCAN; E) download e interpreta&#231;&#227;o via telemedicina por cardiologistas no Brasil e nos Estados Unidos (Sable, C. e Nascimento, B. R.).</title>
              </caption>
              <graphic xlink:href="1678-4170-abc-108-04-0370-70047-gf01-pt.jpg"/></fig>
          </p>
        </sec>
        <sec>
          <title>Resultados iniciais</title>
          <p>A equipe do PROVAR aplicou o processo educativo a mais de 20.000 crian&#231;as sobre CR, e j&#225; realizou mais de 9.000 ecocardiogramas em 32 escolas.<xref ref-type="bibr" rid="B8">8</xref> Na an&#225;lise publicada de 5.996 crian&#231;as assintom&#225;ticas de 21 escolas, a preval&#234;ncia geral de CR foi de 4,2%, incluindo 3,7% de casos borderline (N = 221) e 0,5% de casos definitivos (N = 30). A inclus&#227;o de pacientes n&#227;o-definitivos como rastreamento positivo pode trazer algumas d&#250;vidas, considerando-se os dados dispon&#237;veis; contudo, acreditamos que esta &#233; uma estrat&#233;gia importante, j&#225; que esse grupo parece ter maior risco de progress&#227;o para CR cl&#237;nica (<xref ref-type="fig" rid="f4">Figura 2</xref>).<xref ref-type="bibr" rid="B5">5</xref><sup>,</sup><xref ref-type="bibr" rid="B9">9</xref> Crian&#231;as com sintomas cardiovasculares (autorrelatados ou reportados por pais/professores) que decidiram participar do programa foram encaminhados diretamente para cuidados terci&#225;rios. &#201; importante notar que os ecocardiogramas de rastreamento foram realizados pela equipe n&#227;o-m&#233;dica. Apenas m&#233;dicos t&#234;m autoriza&#231;&#227;o para realizar e interpretar ecocardiogramas no Brasil, e esse estudo foi poss&#237;vel por se tratar de um protocolo de pesquisa.</p>
          <p>
            <fig id="f4">
              <label>Figura 2</label>
              <caption>
                <title>Apresenta&#231;&#227;o progressiva da Cardiopatia Reum&#225;tica ao longo do tempo (adaptada por Carmo, G.A.L. de Z&#252;hlke L.J. e Steer A.C.).<xref ref-type="bibr" rid="B5">5</xref>
								</title>
              </caption>
              <graphic xlink:href="1678-4170-abc-108-04-0370-70047-gf02-pt.jpg"/></fig>
          </p>
          <p>A acur&#225;cia dessa equipe n&#227;o-m&#233;dica (enfermeiros, t&#233;cnicos e estudantes de medicina) para a interpreta&#231;&#227;o b&#225;sica de exames de rastreamento simplificados foi testada e obteve bons resultados: sensibilidade geral de 83% e especificidade de 85%.<xref ref-type="bibr" rid="B10">10</xref> Al&#233;m disso, o processo educacional se mostrou eficaz, com um aumento mediano de 20% no conhecimento sobre CR, avaliado por meio de pr&#233;- e p&#243;s-testes estruturados aplicados a mais de 1.100 alunos.<xref ref-type="bibr" rid="B11">11</xref>
					</p>
        </sec>
        <sec>
          <title>Principais desafios</title>
          <p>Diversos desafios foram encontrados durante a implementa&#231;&#227;o e condu&#231;&#227;o do estudo PROVAR. Durante a aprova&#231;&#227;o &#233;tica inicial - que levou quase 90 dias no Brasil - houve certa resist&#234;ncia das Secretarias de Educa&#231;&#227;o e Sa&#250;de, relacionada principalmente aos procedimentos de pesquisa e ao impacto na rotina escolar. Foram requeridas algumas modifica&#231;&#245;es no termo de consentimento livre e esclarecido, o que levou mais quatro meses. Tamb&#233;m houve questionamentos por parte da Secretaria de Sa&#250;de com rela&#231;&#227;o &#224; transfer&#234;ncia de tarefas (que poderiam ser questionadas pelos Conselhos M&#233;dicos e de Enfermagem) e ao impacto que o rastreamento poderia causar na popula&#231;&#227;o: estrat&#233;gias de encaminhamento, disponibilidade de penicilina para todos os casos positivos - considerando-se a falta de medicamento observada no Brasil - e informa&#231;&#245;es para fam&#237;lias, cujos filhos tivessem exames positivos, para se evitar estigmatiza&#231;&#227;o.</p>
          <p>Durante os primeiros est&#225;gios do estudo de campo, a equipe do PROVAR encontrou diversos desafios. Primeiramente, os principais desafios estiveram relacionados &#224; falta de envolvimento de representantes das escolas com o programa e falta de entendimento com rela&#231;&#227;o aos poss&#237;veis benef&#237;cios. Em geral, o envolvimento dos pais com o projeto foi baixo, e o pior &#237;ndice de participa&#231;&#227;o em sess&#245;es educativas foi visto nas &#225;reas de status socioecon&#244;mico mais baixo. A propor&#231;&#227;o de termos de consentimento livre e esclarecido assinados foi baixa (cerca de 35%: 5.996 de 17.000 crian&#231;as),<xref ref-type="bibr" rid="B8">8</xref> especialmente entre alunos mais velhos, mesmo ap&#243;s o processo educativo. Al&#233;m disso, alguns diretores de escolas recusaram a participa&#231;&#227;o apesar da aprova&#231;&#227;o do comit&#234; de &#233;tica e de autoridades do governo. Por fim, a organiza&#231;&#227;o das crian&#231;as para o rastreamento, principalmente as mais novas, foi um desafio: tirar as crian&#231;as de sala de aula, tirar e p&#244;r as roupas e organiz&#225;-las em fila, coletar dados demogr&#225;ficos, etc. Encontros de follow-up com os Conselhos de Educa&#231;&#227;o e representantes regionais foram agendados regularmente para avaliar fragilidades e necessidades especiais de diferentes comunidades e para incentivar funcion&#225;rios das escolas a apoiarem o projeto localmente. O rastreamento em Centros de Sa&#250;de prim&#225;rios com educa&#231;&#227;o da popula&#231;&#227;o por meio do Programa de Sa&#250;de da Fam&#237;lia - um plano para os pr&#243;ximos anos - tamb&#233;m pode ser uma estrat&#233;gia eficaz para aumentar o escopo do programa.</p>
          <p>Tivemos tamb&#233;m diversas dificuldades em rela&#231;&#227;o &#224;s visitas de seguimento. O contato por telefone com pais muitas vezes n&#227;o foi poss&#237;vel, pois as crian&#231;as n&#227;o tinham as informa&#231;&#245;es de contato, n&#250;meros mudavam com frequ&#234;ncia, e as escolas, muitas vezes, n&#227;o t&#234;m autoriza&#231;&#227;o para divulgar informa&#231;&#245;es de contato. Al&#233;m disso, 35% das fam&#237;lias n&#227;o compareceram &#224;s visitas agendadas. Isso, em parte, pode ser devido ao paciente ser assintom&#225;tico e &#224;s fam&#237;lias n&#227;o estarem convencidas da import&#226;ncia do monitoramento. Com base em conversas com pais que n&#227;o retornaram para o follow-up, nossa equipe suspeita que restri&#231;&#245;es financeiras, resid&#234;ncias em bairros distantes e a impossibilidade de perder um dia de trabalho tamb&#233;m tenham contribu&#237;do para o n&#227;o-seguimento de recomenda&#231;&#245;es de follow-up no protocolo do estudo. Todavia, dados sobre as raz&#245;es da falta de comprometimento n&#227;o foram coletados sistematicamente. Algumas estrat&#233;gias, como liga&#231;&#245;es educativas subsequentes e datas de follow-up flex&#237;veis foram testadas recentemente, e tiveram sucesso relativo. H&#225; tamb&#233;m planos para a realiza&#231;&#227;o de ecocardiogramas de follow-up nas escolas, imediatamente ap&#243;s o processo de rastreamento para melhorar os &#237;ndices de follow-up e encaminhamento. Al&#233;m disso, materiais educativos e p&#250;blicos de conscientiza&#231;&#227;o para diferentes contextos est&#227;o sendo desenvolvidos, considerando-se os questionamentos feitos pelas fam&#237;lias.</p>
        </sec>
        <sec>
          <title>Dire&#231;&#245;es futuras</title>
          <p>A luta contra a CR &#233; um desafio para o Brasil. O entendimento sobre a carga de doen&#231;a e como ela afeta o sistema de sa&#250;de &#233; o objetivo prim&#225;rio do PROVAR. O programa PROVAR continuar&#225; a rastrear a CR em &#225;reas carentes, mas estamos agora expandindo nossos esfor&#231;os para incluir escolas particulares, em que as condi&#231;&#245;es socioecon&#244;micas dos alunos s&#227;o melhores. Estima-se uma preval&#234;ncia muito mais baixa nessa popula&#231;&#227;o "controle".</p>
          <p>As autoridades devem estar preparadas para, de fato, erradicar a CR. Para isso, acreditamos que FRA e CR devem ser inclu&#237;das na lista de doen&#231;as de notifica&#231;&#227;o obrigat&#243;ria, j&#225; que essas doen&#231;as t&#234;m incid&#234;ncia consideravelmente alta no Brasil. Infec&#231;&#245;es estreptoc&#243;cicas do Grupo A (gatilhos para a FRA) s&#227;o contagiosas entre pacientes, e a transmiss&#227;o pode ser eliminada com a erradica&#231;&#227;o.<xref ref-type="bibr" rid="B12">12</xref> Al&#233;m disso, ao identificar CR precocemente, profilaxia secund&#225;ria pode ser iniciada para prevenir a progress&#227;o da doen&#231;a e consequ&#234;ncias tardias como insufici&#234;ncia card&#237;aca, arritmias, acidente vascular encef&#225;lico e cirurgias de v&#225;lvulas card&#237;acas.</p>
          <p>Os pr&#243;ximos passos do PROVAR est&#227;o relacionados &#224; integra&#231;&#227;o diagonal do rastreamento de CR &#224; aten&#231;&#227;o prim&#225;ria. Essa estrat&#233;gia est&#225; agora sendo implementada em Montes Claros (2 centros de cuidados prim&#225;rios j&#225; foram inscritos) e ser&#225; lan&#231;ada em Belo Horizonte e Nova Lima nos pr&#243;ximos meses, incluindo tamb&#233;m o rastreamento para outras doen&#231;as valvares degenerativas e cong&#234;nitas. Para tal, m&#233;dicos da aten&#231;&#227;o prim&#225;ria ser&#227;o treinados para aquisi&#231;&#227;o de imagens ecocardiogr&#225;ficas b&#225;sicas para avalia&#231;&#245;es de rotina de diferentes faixas et&#225;rias, usando a mesma infraestrutura de telemedicina para armazenamento e interpreta&#231;&#227;o de imagens. Acreditamos que tal integra&#231;&#227;o &#233; um passo crucial para uma sustentabilidade em longo prazo de rastreamento ecocardiogr&#225;fico e para sua integra&#231;&#227;o em pol&#237;ticas de sa&#250;de, e permitir&#225; a avalia&#231;&#227;o da estrat&#233;gia ideal de rastreamento, incluindo uma an&#225;lise de custo-efetividade. Caso o rastreamento de CR nesses contextos se mostre vi&#225;vel e custo-efetivo, o passo final ser&#225; inclu&#237;-lo como prioridade na discuss&#227;o do or&#231;amento do sistema p&#250;blico de sa&#250;de a longo prazo.</p>
        </sec>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="supported-by">
          <p>
            <bold>Fontes de financiamento</bold>
          </p>
          <p>O presente estudo foi financiado pelo Verizon Foundation (U.S.A.), Funda&#231;&#227;o de Amparo &#224; Pesquisa de Minas Gerais (FAPEMIG) e Conselho Nacional de Desenvolvimento CIent&#237;fico e Tecnol&#243;gico (CNPq).</p>
        </fn>
        <fn fn-type="other">
          <p>
            <bold>Vincula&#231;&#227;o acad&#234;mica</bold>
          </p>
          <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
        </fn>
      </fn-group>
      <ack>
        <title>Agradecimentos</title>
        <p>Os investigadores do PROVAR gostariam de agradecer a <italic>Verizon</italic> pelo apoio e financiamento do programa, a <italic>General Electric Healthcare</italic> por proporcionar o equipamento ecocardiogr&#225;fico para este programa e a <italic>ViTel Net</italic>&#174; por sua colabora&#231;&#227;o e contribui&#231;&#227;o na cria&#231;&#227;o de uma plataforma de nuvem de CR e &#224; Edwards Foundation pelo apoio ao programa de ecocardiografia na aten&#231;&#227;o prim&#225;ria. A Rede de Teleassist&#234;ncia de Minas Gerais foi financiada pelo Governo do Estado de Minas Gerais, pela Secretaria de Estado da Sa&#250;de de Minas Gerais e pela FAPEMIG (Funda&#231;&#227;o de Amparo &#224; Pesquisa de Minas Gerais), e pelo Governo Brasileiro, incluindo o Minist&#233;rio da Sa&#250;de e Minist&#233;rio da Ci&#234;ncia, Tecnologia, Inova&#231;&#227;o e Comunica&#231;&#245;es e suas ag&#234;ncias de pesquisa e inova&#231;&#227;o, CNPq (Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico) e FINEP (Financiadora de Estudos e Projetos).</p>
      </ack>
    </back>
  </sub-article>
</article>
